1. Search Result
Search Result
Results for "

male dogs

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-170419

    Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 10 is an agonist of the APJ Receptor. APJ receptor agonist 10 can be used for research on pulmonary arterial hypertension .
    APJ receptor agonist 10
  • HY-B0708
    β-Estradiol 17-acetate
    1 Publications Verification

    1,3,5(10)-Estratriene-3,17β-diol 17-acetate

    Estrogen Receptor/ERR Endocrinology
    β-Estradiol 17-acetate (1,3,5(10)-Estratriene-3,17β-diol 17-acetate) is a long-acting endogenous estrogen precursor and also a cell viability and proliferation enhancer. β-Estradiol 17-acetate promotes the adhesion and proliferation of freshly isolated and revived female-derived human brain microvascular endothelial cells, and reverses the decreased viability of revived male-derived human brain microvascular endothelial cells. β-Estradiol 17-acetate exerts the microvascular protective effect of estrogen, enabling non-tumor human brain microvascular endothelial cells to be cultured in vitro for 2 months after cryopreservation. β-Estradiol 17-acetate is biotransformed into β-estradiol via hydrolase action in the in vitro skin of humans, hairless dogs, rats and hairless mice .
    β-Estradiol 17-acetate
  • HY-B1017

    EN-1733A

    Dopamine Receptor Neurological Disease
    Molindone hydrochloride (EN-1733A) is an orally active and brain-penetrant dopamine D2/D5 receptor antagonist. Molindone hydrochloride shows antipsychotic and antidepressant-like activities. Molindone hydrochloride suppresses spontaneous locomotion, and antagonizes apomorphine-induced emesis. Molindone hydrochloride can be used for the research of neurological disease .
    Molindone (hydrochloride)
  • HY-17549

    CRL 40028

    Adrenergic Receptor Neurological Disease
    Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
    Adrafinil
  • HY-B1849

    Environmental Pollutants Herbicide Others
    Hexazinone is a triazinone herbicide with high mobility and persistence in soil. Hexazinone is mainly degraded by soil microorganisms, and its degradation and mineralization processes are significantly affected by soil texture (faster in clay loam) and application method (mixed application can improve its bioavailability and mineralization rate). Hexazinone exhibits mild to moderate acute oral toxicity and has significant eye irritation .
    Hexazinone
  • HY-19771

    GSK294; amyloid P-IN-1

    Amyloid-β Neurological Disease
    GSK3039294 is an orally active pro-drug of Miridesap (HY-101861), a circulating serum amyloid P component depleter. GSK3039294 undergoes hydrolysis to form miridesap via a monoester intermediate. GSK3039294 can be used for the research of systemic amyloidosis .
    GSK 3039294
  • HY-144074

    LRRK2 Neurological Disease
    LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
    LRRK2-IN-4
  • HY-177298

    Phosphodiesterase (PDE) Others
    PDE5-IN-15 (compound 21) is a xanthine derivative and PDE5 inhibitor, with IC50 values of 0.002, 0.180, 2.85 and 2.22 μM against hPDE5, bPDE6, bPDE1 and hPDE3, respectively. PDE5-IN-15 has good oral bioavailability in dogs. PDE5-IN-15 can be used in research on male erectile dysfunction .
    PDE5-IN-15
  • HY-W982689

    Biochemical Assay Reagents Metabolic Disease
    Fluindarol is a phenylindandione derivative and an orally active anticoagulant. Fluindarol acts as a toxicant that induces organ and tissue haemorrhages and liver parenchymal necrosis in rats. Fluindarol exhibits acute and cumulative preclinical toxicity in rats, rabbits, and dogs, with higher toxicity in female rats than male rats. Fluindarol lacks analgesic action, produces only minor blood pressure effects, and does not alter circulation, respiration, CNS, or cardiac activity. Fluindarol is considered too toxic for clinical use based on preclinical data .
    Fluindarol
  • HY-182320

    CETP Cardiovascular Disease
    DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease .
    DRL-17822
  • HY-183318

    PPAR Metabolic Disease
    PPARα/δ agonist 4 is a potent orally active and selective dual peroxisome proliferator-activated receptor (PPAR) α/δ agonist with EC50s of 0.36 and 1.31 nM, respectively. PPARα/δ agonist 4 exhibits >123-fold selectivity over PPARγ (EC50 = 160.84 nM). PPARα/δ agonist 4 upregulates expression of downstream fatty acid oxidation genes PDK4, CPT1A, and ACADVL. PPARα/δ agonist 4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    PPARα/δ agonist 4
  • HY-183138

    Drug Metabolite Cardiovascular Disease
    N-Demethyldiltiazem is a metabolite of Diltiazem (HY-B0632). N-Demethyldiltiazem increases coronary blood flow, modulates cardiac function, decreases systemic blood pressure and heart rate, and alters papillary muscle developed tension .
    N-Demethyldiltiazem
  • HY-182589

    FAAH Potassium Channel Neurological Disease Metabolic Disease
    SRP-001 is an orally active, blood-brain barrier-permeable analgesic and antipyretic agent. SRP-001 reduces the expression level of FAAH, mildly inhibits hERG currents, generates AM404 (HY-101388), and maintains the integrity of hepatic tight junctions. SRP-001 exerts analgesic, antipyretic, and antinociceptive effects .
    SRP-001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: